Lantus Solostar (Insulin Glargine)

Insulin glargine binds to insulin receptors, promoting glucose uptake in muscle and fat cells while suppressing hepatic glucose production. Its formulation creates a slow, continuous release after subcutaneous injection, delivering a steady basal insulin effect for up to 24 hours.

The dose of Lantus Solostar is individualized and determined by a qualified prescriber based on the patient’s blood‑glucose monitoring, body weight, diet, and overall treatment plan. No fixed dosing regimen is provided here.

Insulin glargine may be used during pregnancy or lactation only if the potential benefits justify the potential risks. Decisions should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lantus Solostar (insulin glargine) offers a once‑daily, long‑acting basal insulin profile with minimal peak effect, similar to other insulin glargine products. Compared with intermediate‑acting insulins like NPH, it provides more predictable glucose control and a lower risk of nocturnal hypoglycemia.

Lantus Solostar should be stored in a refrigerator at 2‑8 °C, protected from light, and must not be frozen or shaken. Once in use, the vial can be kept at room temperature (up to 30 °C) for a maximum of 28 days, as indicated on the label.

Lantus Solostar is administered by subcutaneous injection, typically once daily at the same time each day. Injection sites may include the abdomen, thigh, or upper arm, rotating sites to reduce local reactions.

The most serious risks include severe hypoglycemia, which can lead to loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs and seek immediate medical attention if they occur.

Lantus Solostar should not be used by individuals with known hypersensitivity to insulin glargine or any of its excipients. Caution is also advised for patients with severe renal or hepatic impairment, and it is contraindicated in cases of hypoglycemia.